Cannabis News
Let People Die in Peaceful Bliss
The Advanced Integrative Medical Science Institute (AIMS), a clinic co-founded by Dr. Sunil Aggarwal, has launched a lawsuit against the Drug Enforcement Administration (DEA). According to the lawsuit, Dr. Aggarwal was wrongfully refused clearance by the DEA to give psilocybin to patients who are near death. Dr. Aggarwal attempted to make advantage of Washington state’s “Right-to-Try” Act, which permits the use of experimental drugs for end-of-life treatment.
Court filings reveal that Dr. Aggarwal asked the DEA for authorization to administer psilocybin to patients on many occasions, but each time he received an unjustified denial. The Controlled Substances Act classifies psilocybin as a Schedule I substance because it has historically been shown to have no known therapeutic benefits. Nonetheless, the records mentioned that psilocybin is presently undergoing stage III clinical studies and has been given the designation of “breakthrough therapy status” by the FDA twice.
The court filing stressed that if the DEA refuses to grant Dr. Aggarwal access to psilocybin under both the CSA and RTT, it must justify its decision based on legal statutes and established agency precedents. It’s worth noting that Dr. Aggarwal holds a DEA license allowing him to prescribe drugs classified under schedules II–V.
Furthermore, the document outlined Dr. Aggarwal’s efforts to obtain permission from the DEA. Initially, he argued for the use of psilocybin under RTT laws without needing a special permit, but this was denied. He then requested a special waiver, citing previous instances where similar waivers had been granted for the therapeutic use of cannabis in pediatric cases. Despite presenting such precedents, Dr. Aggarwal’s requests were consistently rejected, leading to his demand for a coherent explanation from the DEA regarding its decision in light of existing regulations and precedents.
Patients in the advanced stages of cancer
Dr. Aggarwal attends to individuals grappling with advanced-stage cancer, among whom are those enduring severe and incapacitating anxiety and depression unresponsive to FDA-approved treatments. Drawing upon his professional expertise and evaluations of his patients, Dr. Aggarwal explored the potential of psilocybin therapy with certain individuals, discussing both the associated risks and potential benefits. He stated that these patients expressed a willingness to undergo psilocybin treatment after providing informed consent.
Kathryn L. Tucker, representing Aggarwal and AIMS alongside the National Psychedelics Association, conveyed to Law360 that the prolonged legal disputes resulting from the DEA’s refusals have impeded access to a drug that physicians believe could alleviate the anxiety and depression of terminally ill patients.
“Right to Try aims to grant terminally ill patients access to promising experimental medications, recognizing the urgency of their situation and the impracticality of waiting for the lengthy process of new drug approval to conclude,” Tucker emphasized.
Prolonged Struggle
The doctor and the DEA have been at odds over his attempts to provide psilocybin to patients who are near death for a number of years. But as the brief states, the DEA stated in 2022 that it did not believe that giving the medication to individuals who were near death would be in keeping with public health and safety.
Additionally, the doctor contends in his brief that instead of allowing him to offer the drug under Right to Try (RTT) provisions, the DEA insisted he register as a researcher to procure the drugs for his patients. Dr. Aggarwal argues that this requirement would compel him to develop a study protocol and seek FDA approval, contradicting the RTT law.
Furthermore, Law360 reported on a related case where a Ninth Circuit panel in October instructed the DEA to elucidate its rationale for maintaining psilocybin as a Schedule I substance. This directive came after the agency summarily dismissed Aggarwal’s petition to reclassify psilocybin as Schedule II, a category reserved for drugs with currently accepted medical use under severe restrictions.
Legal Challenges and Ethical Imperatives
The legal battle between Dr. Aggarwal and the DEA encapsulates broader legal challenges and ethical considerations surrounding access to novel treatments for terminal illnesses. On one hand, the DEA’s refusal to grant clearance for psilocybin treatment underscores the regulatory complexities and bureaucratic hurdles that physicians and patients face in accessing experimental therapies. The case raises questions about the DEA’s interpretation and application of existing statutes, particularly in the context of end-of-life care and patients’ rights to pursue alternative treatments under Right-to-Try laws.
Furthermore, the disagreement touches on basic ethical requirements in the medical field in addition to the legal nuances. It is urgent and compassionate to provide terminally ill patients with access to potentially helpful medicines since they frequently face excruciating pain and few alternatives for therapy. Dr. Aggarwal’s support of psilocybin therapy highlights the moral need of putting patients’ welfare and autonomy first, especially when traditional therapies have failed to adequately relieve patients’ symptoms and misery.
In the end, the legal issues surrounding Dr. Aggarwal’s attempts to give terminally sick patients psilocybin highlight the necessity of a sophisticated strategy that strikes a balance between legal requirements and moral obligations. As the case develops, it demands for a compassionate and evidence-based approach to guarantee that patients with life-limiting illnesses can access potentially beneficial therapies in a timely and dignified manner. It also prompts a critical examination of the current regulatory framework governing access to experimental treatments.
Bottom Line
In conclusion, the lawsuit filed by Dr. Aggarwal against the DEA represents a pivotal moment in the ongoing discourse surrounding access to innovative treatments for terminally ill patients. The legal battle highlights the intricate interplay between regulatory frameworks, ethical considerations, and the imperative to prioritize patient welfare. As the case unfolds, it prompts a critical reevaluation of existing laws and policies governing access to experimental therapies, particularly in the context of end-of-life care. Beyond legal complexities, the dispute underscores the moral obligation to provide compassionate and evidence-based care to individuals facing life-limiting illnesses. Dr. Aggarwal’s advocacy for psilocybin therapy serves as a poignant reminder of the importance of patient autonomy and the relentless pursuit of solutions to alleviate suffering. Ultimately, the outcome of this legal challenge will have far-reaching implications for the broader healthcare landscape, shaping the future of access to innovative treatments for terminally ill patients.
HOW TO INGEST MUSHROOMS SO THEY TASTE GOOD, READ ON…
“How Long Does One Puff of Weed Stay in Your System?”… This topic can be difficult to answer since it is dependent on elements such as the size of the hit and what constitutes a “one hit.” If you take a large bong pull then cough, it might linger in your system for 5-7 days. A moderate dose from a joint can last 3-5 days, whereas a few hits from a vaporizer may last 1-3 days.
The length of time that marijuana stays in the body varies based on a number of factors, including metabolism, THC levels, frequency of use, and hydration.
Delta-9-tetrahydrocannabinol, or THC, is the primary psychoactive component of cannabis. THC and its metabolites, which remain in your body long after the effects have subsided, are detected by drug tests.
Since these metabolites are fat-soluble, they cling to bodily fat molecules. They could thus take a while to fully pass through your system, particularly if your body fat percentage is higher.
THC is absorbed by tissues and organs (including the brain, heart, and fat) and converted by the liver into chemicals such as 11-hydroxy-THC and carboxy-THC. Cannabis is eliminated in feces at a rate of around 65%, while urine accounts for 20%. The leftover amount might be kept within the body.
THC deposited in bodily tissues ultimately re-enters the circulation and is processed by the liver. For frequent users, THC accumulates in fatty tissues quicker than it can be removed, thus it may be detectable in drug tests for days or weeks following consumption.
The detection time varies according to the amount and frequency of cannabis usage. Higher dosages and regular usage result in longer detection times.
The type of drug test also affects detection windows. Blood and saliva tests typically detect cannabis metabolites for shorter periods, while urine and hair samples can reveal use for weeks or even months. In some cases, hair tests have detected cannabis use over 90 days after consumption.
Detection Windows for Various Cannabis Drug Tests
Urine Tests
Among all drug tests, urine testing is the most commonly used method for screening for drug use in an individual.
Detection times vary, but a 2017 review suggests the following windows for cannabis in urine after last use:
– Single-use (e.g., one joint): up to 3 days
– Moderate use (around 4 times a week): 5–7 days
– Chronic use (daily): 10–15 days
– Chronic heavy use (multiple times daily): over 30 days
Blood Tests
Blood tests generally detect recent cannabis use, typically within 2–12 hours after consumption. However, in cases of heavy use, cannabis has been detected up to 30 days later. Chronic heavy use can extend the detection period in the bloodstream.
Saliva Tests
THC can enter saliva through secondhand cannabis smoke, but THC metabolites are only present if you’ve personally smoked or ingested cannabis.
Saliva testing has a short detection window and can sometimes identify cannabis use on the same day. A 2020 review found that THC was detectable in the saliva of frequent users for up to 72 hours after use, and it may remain in saliva longer than in blood following recent use.
In areas where cannabis is illegal, saliva testing is often used for roadside screenings.
Hair Tests
Hair follicle tests can detect cannabis use for up to 90 days. After use, cannabinoids reach the hair follicles through small blood vessels and from sebum and sweat surrounding the hair.
Hair grows at approximately 0.5 inches per month, so a 1.5-inch segment of hair close to the scalp can reveal cannabis use over the past three months.
Factors Affecting THC and Metabolite Retention
The length of time THC and its metabolites stay in your system depends on various factors. Some, like body mass index (BMI) and metabolic rate, relate to individual body processing, not the drug itself.
Other factors are specific to cannabis use, including:
– Dosage: How much you consume
– Frequency: How often you use cannabis
– Method of consumption: Smoking, dabbing, edibles, or sublingual
– THC potency: Higher potency can extend detection time
Higher doses and more frequent use generally extend THC retention. Cannabis consumed orally may remain in the system slightly longer than smoked cannabis, and stronger cannabis strains, higher in THC, may also stay detectable for a longer period.
How Quickly Do the Effects of Cannabis Set In?
When smoking cannabis, effects appear almost immediately, while ingested cannabis may take 1–3 hours to peak.
The psychoactive component THC produces a “high” with common effects such as:
– Altered senses, including perception of time
– Mood changes
– Difficulty with thinking and problem-solving
– Impaired memory
Other short-term effects can include:
– Anxiety and confusion
– Decreased coordination
– Dry mouth and eyes
– Nausea or lightheadedness
– Trouble focusing
– Increased appetite
– Rapid heart rate
– Restlessness and sleepiness
In rare cases, high doses may lead to hallucinations, delusions, or acute psychosis.
Regular cannabis use may have additional mental and physical effects. While research is ongoing, cannabis use may increase the risk of:
– Cognitive issues like memory loss
– Cardiovascular problems including heart disease and stroke
– Respiratory illnesses such as bronchitis or lung infections
– Mood disorders like depression and anxiety
Cannabis use during pregnancy can negatively impact fetal growth and development.
Duration of Effects
Short-term effects generally taper off within 1–3 hours, but for chronic users, some long-term effects may last days, weeks, or even months. Certain effects may even be permanent.
Bottom Line
The amount of time that cannabis remains in your system following a single use varies greatly depending on individual characteristics such as body fat, metabolism, frequency of use, and mode of intake. Frequent users may maintain traces of THC for weeks, whereas infrequent users may test positive for as little as a few days. Hair tests can disclose usage for up to 90 days, while blood and saliva tests identify more recent use. Urine tests are the most popular and have varying detection durations. The duration that THC and its metabolites are detectable will ultimately depend on a number of factors, including dose, strength, and individual body chemistry.
PEE IN A CUP COMING UP, READ ON..
Is kratom addictive? Discover the potential for dependence on Kratom, the risks involved with its use, and how to approach its consumption responsibly.
From 2011 to 2017, over 1,800 calls to poison centers involved kratom in the U.S. This significant number highlights the concern regarding kratom addiction.
However, without Food and Drug Administration (FDA) oversight, and due to various consumption methods like teas and capsules, there are significant health risks. Safe use of kratom is now in question due to these issues.
Research debates how dependence develops, outlining signs like loss of control and withdrawal symptoms. These signs are seen in regular kratom users. Ironically, some people switch from drugs like heroin to kratom, looking for a legal alternative.
Understanding Kratom: Origins and Prevalence
Kratom comes from the Mitragyna speciosa tree in Southeast Asia. It can act like a stimulant or like opioids, based on how much you take. People use it in different ways, for a small energy boost or stronger effects at higher doses.
The legal status of kratom in the U.S. is complicated and changing. It’s a hot topic because some worry about its misuse. It’s still legal in several states. This shows how different places handle drug rules. The National Institute on Drug Abuse is looking into its medical benefits. But, the FDA hasn’t approved it for medical use yet. The DEA calls it a “drug of concern,” which means policies might change.
-
From 2011 to 2017, poison control centers in the U.S. got over 1,800 reports about kratom. This shows it’s widely used and might pose health risks.
-
Kratom’s main ingredients bind to opioid receptors very strongly, stronger than morphine even. This fact is key to understanding its effects.
-
As more people use kratom, more are reporting serious health problems. These include liver and heart issues, and tough withdrawal symptoms, particularly in those already sick.
The statistics show mounting worries about kratom in the U.S. As its use grows, it’s becoming more important to health policies and laws. What happens next will depend on further research and legal decisions.
Is Kratom Addictive: Investigating the Substance’s Nature
The question of kratom’s addictiveness focuses on how it affects brain receptors and its long-term health implications. The ongoing debate highlights concerns about dependence and the risk of addiction. Scientists are closely looking at these issues.
How Kratom Works in the Brain
Kratom’s main alkaloids, mitragynine and 7-hydroxymitragynine, bind to the brain’s opioid receptors, similar to painkillers and narcotics. This connection suggests a potential risk of dependence. These alkaloids are key to kratom’s pain relief but also point to possible addiction concerns, especially with frequent, high-dose usage.
Patterns and Consequences of Long-term Use
-
Using kratom often, especially in large doses, can increase the risk of dependence and intense withdrawal symptoms, similar to opioid withdrawal.
-
Although some use it for pain or to improve mood, long-term kratom users might see serious health problems, like liver damage and mental health issues.
-
Withdrawal symptoms, including irritability, nausea, and sleep problems, show kratom’s impact on one’s physical and mental health.
Assessment of Addiction Risks
Studies indicate a significant risk of addiction to kratom, especially with high doses or frequent use. Dependence develops as the body gets used to kratom, leading to tolerance and a need for more to feel its effects. Withdrawal symptoms emphasize this risk, as highlighted by health experts.
Physiological Effects: Kratom’s Impact on the Body
There is a lot of debate about the safety and use of kratom. This herbal extract comes from the Mitragyna speciosa plant. It has drawn attention for its possible harmful effects on the body. The FDA has issued many warnings about kratom, raising safety concerns.
-
Kratom Adverse Effects: Kratom users have reported side effects like nausea, vomiting, and confusion. More serious issues include high blood pressure and liver damage. These problems highlight the risks of using kratom.
-
Herbal Extract Safety: Some kratom products contain heavy metals and pathogens. These can cause severe health issues, including death. This shows the importance of safety in herbal products.
-
FDA Warnings and Regulations: The FDA has linked kratom to over 35 deaths and warns against using it. They point out the lack of medical uses and the risk of addiction.
-
Physiological Impact: Kratom’s effects depend on the dose and the user’s body. Yet, it can lead to dangerous outcomes like liver damage and seizures.
-
Safety Concerns from Authorities: Federal agencies like the DEA are worried about kratom’s safety. Although not a controlled substance, monitoring suggests users should be careful.
Kratom might offer temporary relief for some ailments, but it comes with significant risks. The FDA’s warnings should make people think twice. If considering kratom, it’s crucial to talk to a doctor first. Experts stress the need for safety and caution with herbal extracts.
Conclusion
Kratom’s role in health and regulation is complex, with views and research findings widely varied. Some people use kratom for its claimed health benefits, but it’s a hot topic. Experts advise caution and suggest consulting a doctor before using kratom due to the unclear effects.
Clinical studies using scores like SOWS and COWS haven’t confirmed withdrawal symptoms from kratom. This adds to the debate, especially when some users report withdrawal. This makes kratom a controversial subject among different findings and user experiences.
When it comes to treating opioid addiction, kratom can be both helpful and harmful. Some have used it successfully to fight addiction. Yet, some states have banned it. This highlights the need for regulations and consistent product quality. It also raises questions about kratom’s legal status due to mixed actions by authorities.
The situation shows how complex kratom is in the realm of substance use and law. Without clear evidence supporting either its benefits or risks, it poses a challenge. More research is needed to guide regulations and health advice. For now, anyone thinking of using kratom should be careful, seek medical advice, and keep up with laws and health guidelines.
WHAT IS KRATOM ANYWAY? READ ON…
Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em
I Had Just One Puff
Marijuana firms Eaze, Green Dragon find new life after $10 million capital infusion
Get some rest on Modified Grapes—November’s Leafly HighLight
Is Kratom Addictive? Understanding Dependence, Risks, and Safe Usage
New Rule, December 5: Oregon Cannabis Retailers, Processors and Labor Peace Agreements
The CBD Dog Treat Guide
Trippin’ Golf Balls – Can Magic Mushrooms Help Your Golf Game?
Australian Broadcasting Corp Alleges Military Veterans Have Been Targeted By Medicinal Cannabis Companies Via Social Media & Offered Free “Product”
Medical Marijuana Passed in 106 out of 106 Counties and Cities in What State? A. Florida B. Kentucky C. Ohio D. North Dakota
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
City Of Oakland Issues RFP For Employee Training Programs
-
Cannabis News2 years agoDistressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years agoUnited States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years agoWhat you Need to Know
-
drug testing11 months agoDrug Testing for Marijuana – The Joint Blog
-
Education2 years agoNCIA Write About Their Equity Scholarship Program
-
Cannabis2 years agoIt has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years agoCannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years agoA new April 20 cannabis contest includes a $40,000 purse